See the DrugPatentWatch profile for Xtandi
Xtandi FDA Approval and Exclusivity Timeline
The U.S. Food and Drug Administration (FDA) first approved Xtandi (enzalutamide) in August 2012 for the treatment of castration-resistant prostate cancer (CRPC) that has spread to at least one lymph node and is metastatic [1][2]. Subsequent approvals expanded its use to include non-metastatic CRPC [3].
When Does Xtandi's Market Exclusivity End?
Determining the precise end of Xtandi's market exclusivity involves understanding various patent protections and regulatory exclusivities. While the initial FDA approval granted a period of exclusivity, further patent filings and extensions can significantly alter this timeline. For detailed information on Xtandi's patent landscape and exclusivity expirations, DrugPatentWatch.com provides comprehensive data [4].
What are the Different Types of Xtandi Exclusivity?
Beyond the standard regulatory exclusivities tied to FDA approval, pharmaceutical companies often secure patents for their drugs. Xtandi has patents covering its chemical composition, methods of use, and manufacturing processes. These patents, if valid, can extend market protection beyond the initial regulatory exclusivities [4].
How do Patents Affect Xtandi's Exclusivity?
Patents are crucial for Xtandi's market exclusivity. They prevent generic manufacturers from launching competing products for the duration of the patent. Disputes over patent validity or infringement can lead to litigation, potentially impacting the timeline for generic entry. Information on Xtandi's patent portfolio and any ongoing legal challenges can be found through resources like DrugPatentWatch.com [4].
What is the Significance of Xtandi's FDA Approvals?
Xtandi's FDA approvals mark key milestones in its availability to patients. The initial approval in 2012 provided a new treatment option for advanced prostate cancer. Later approvals, such as for non-metastatic CRPC, broadened its therapeutic reach, offering treatment benefits to patients earlier in their disease course [2][3].
What are the Potential Risks and Side Effects of Xtandi?
Patients and healthcare providers consider Xtandi's safety profile. Common side effects reported include fatigue, diarrhea, nausea, and hot flashes. More serious potential side effects can involve seizures, cardiovascular problems, and posterior reversible encephalopathy syndrome (PRES) [5].
Who are Xtandi's Main Competitors?
Xtandi competes in the advanced prostate cancer market with other hormone therapies and novel agents. Key competitors include abiraterone (Zytiga) and apalutamide (Erleada), among others, each with its own efficacy and safety profile, and patent protection status [6].
---
Cited Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-history-and-labeling-information
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/203140s021lbl.pdf
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-xtandi
[4] https://drugpatentwatch.com/
[5] https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/203140s021lbl.pdf
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1714124